Nkarta, Inc.
Clinical-stage biotechnology company developing allogeneic, off-the-shelf natural killer (NK) cell therapies for B cell-mediated autoimmune diseases. Combines donor-derived NK cell collection, genetic engineering (CARs and membrane-bound cytokine expression), large-scale expansion, cryopreservation and GMP manufacturing to support multicenter Phase 1/2 clinical programs and translational research.
Industries
Nr. of Employees
medium (51-250)
Nkarta, Inc.
Products
CD19-targeting allogeneic CAR NK cell therapy (investigational)
Donor-derived NK cells genetically engineered to express a CAR targeting CD19 and membrane-bound IL-15, expanded at scale, cryopreserved and intended for off-the-shelf administration to deplete pathogenic B cells.
CD19-targeting allogeneic CAR NK cell therapy (investigational)
Donor-derived NK cells genetically engineered to express a CAR targeting CD19 and membrane-bound IL-15, expanded at scale, cryopreserved and intended for off-the-shelf administration to deplete pathogenic B cells.
Services
Enrollment and operational support for multicenter Phase 1/2 trials, provider fact sheets and direct clinical referrals to study sites.
Enrollment and operational support for multicenter Phase 1/2 trials, provider fact sheets and direct clinical referrals to study sites.
Expertise Areas
- Allogeneic cell therapy development
- NK cell engineering and CAR design
- Large-scale cell manufacturing and cryopreservation
- Gene editing for immune cell enhancement
Key Technologies
- Chimeric antigen receptor (CAR) engineering
- CRISPR-Cas9 gene editing
- Membrane-bound interleukin-15 engineering
- Donor leukapheresis-derived cell sourcing
News & Updates
Multiple poster and oral presentations reporting preclinical data, gene-editing strategies, expansion processes and early clinical data across scientific conferences.
Press/article coverage highlighting the potential of engineered natural killer cells to reset disordered immune systems.
Started dosing and patient enrollment in multicenter Phase 1/2 trials evaluating the investigational allogeneic CAR NK therapy in multiple autoimmune conditions.
Multiple poster and oral presentations reporting preclinical data, gene-editing strategies, expansion processes and early clinical data across scientific conferences.
Press/article coverage highlighting the potential of engineered natural killer cells to reset disordered immune systems.
Started dosing and patient enrollment in multicenter Phase 1/2 trials evaluating the investigational allogeneic CAR NK therapy in multiple autoimmune conditions.